Maraviroc increases CCR5 expression on immune cells. (A-C) Expression of CCR5 by MFI at day 30 and day 60 in control and maraviroc-treated patients on CD4⁺ T cells (A), CD8⁺ T cells (B), and CD19⁺ B cells (C). (D-F) Expression of CXCR3 by MFI at day 30 and day 60 in control patients and maraviroc-treated patients on CD4⁺ T cells (D), CD8⁺ T cells (E), and CD19⁺ B cells (F). *P < .05, **P < .01, Student t test.